🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our CEO Sek Kathiresan MD, sat down with Brad Loncar to discuss the positive initial data from our Heart-2 Phase 1b clinical trial of VERVE-102. We're encouraged by our progress to date and are looking forward to dosing the first patient in the Phase 2 study in the second half of 2025,

Verve was founded seven years ago with a vision of one treatment dose potentially leading to a lifetime reduction of low-density lipoprotein cholesterol (LDL-C) levels. Initial data from the Heart-2 Phase 1b clinical trial showed a strong dose-dependent response with total RNA

Today is #DNAday, a day to celebrate the discovery of DNA's double helix structure and one of the most groundbreaking moments in science. This discovery paved the way for the field of genetics, and today, it's the foundation of the work we do every day at Verve. We’re utilizing a

We’re looking forward to presenting at the #EASCongress2025 next week. For those on site, tune into our presentation which includes a discussion of the initial positive data from our Heart-2 trial of VERVE-102. You can also visit us at booth 7B! Learn more about the event here:

The PCSK9 gene is a key regulator of cholesterol in the liver. At Verve, we are developing VERVE-102, a single-course #geneediting medicine, designed to permanently turn off the PCSK9 gene in the liver to reduce blood LDL-C, (also known as the “bad cholesterol”) levels in people

Our team had a wonderful time at the #EASCongress2025 presenting recent highlights from our PCSK9 program and Verve’s vision of a one dose future to address #cardiovasculardisease. View the EAS presentation here: vervetx.com/sites/default/…

Earlier this week we were honored to receive the SciSci Trailblazer award from Science from Scientists. Since beginning our partnership in 2021, we’ve been inspired by their mission to ignite curiosity and empower the next generation of #STEM innovators. We are proud to give back and help

One question we ask ourselves is: Can we develop a single-course #baseediting treatment that mimics natural PCSK9 variants to generate enduring efficacy? That’s what our goal is with VERVE-102. At #EASCongress2025, we presented recent findings from our Heart-2 Phase 1b clinical

Today, we reported pipeline updates and financial results for Q1 2025. Read the full announcement, as well as an overview of our programs here: ir.vervetx.com/news-releases/…

Verve is dedicated to developing transformative #geneediting medicines. We were thrilled to be selected once again to design cover art for ACS Publications. The latest issue of Analytical Chemistry features our latest publication on how top-down mass spectrometry combined with

Our co-founder and CEO Sek Kathiresan MD will be presenting at the RBC Capital Markets Global Healthcare Conference in New York next week. Join us on Wednesday, May 21 as we discuss our mission to transform the treatment of #cardiovascular disease through single-course gene editing

Heading to the #TIDESUSA 2025 Oligonucleotide & Peptide Therapeutics conference in San Diego? Don’t miss our Chief Scientific Officer Troy Lister’s, Ph.D. presentation discussing how Verve utilizes #geneediting to potentially lower cholesterol to treat #cardiovascular disease on

On #ClinicalTrialsDay, we honor the people who power our purpose: the participants, investigators, and teams behind every trial. Every individual who takes part in a clinical trial plays a vital role in advancing science, accelerating innovation, and helping pave the way for a

As part of the STEM Day at Fenway event, a few lucky Vervians spent the afternoon with students at the ballpark exploring the world of science through interactive demonstrations and hands-on activities. We love partnering with Science from Scientists to inspire the next generation of

Members of the Verve leadership team will be participating in two upcoming healthcare investor conferences. We’re looking forward to connecting with the investment community to share updates on our progress and our mission to transform the treatment of #cardiovascular disease

Cholesterol is more than just a number! It plays a major role in heart health. Keeping LDL (bad) and HLD (good) cholesterol levels in check is key to reducing your risk of heart disease and stroke. Watch the video from American Heart Association to learn more: youtube.com/watch?v=UaolDz…

At Verve, collaboration is more than a buzzword — it’s how breakthroughs begin. Whether we’re in the lab, in meetings, or sharing a coffee break, we believe that diverse voices and open minds drive bold science.